Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10

SIMPLE SUMMARY: In general, brachytherapy (BT) improves biochemical control in intermediate-to high-risk prostate cancer. We previously reported that importance of very high-risk factors (VHR: T3b–4 or Gleason score 9–10) and patients with double VHR (VHR-2) showed the worst prognosis among high-ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Hideya, Suzuki, Gen, Masui, Koji, Aibe, Norihiro, Shimizu, Daisuke, Kimoto, Takuya, Yamada, Kei, Okihara, Koji, Ueda, Takashi, Narukawa, Tsukasa, Shiraishi, Takumi, Fujihara, Atsuko, Yoshida, Ken, Nakamura, Satoaki, Kato, Takashi, Hashimoto, Yasutoshi, Okabe, Haruumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221358/
https://www.ncbi.nlm.nih.gov/pubmed/35740639
http://dx.doi.org/10.3390/cancers14122976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221358/
https://www.ncbi.nlm.nih.gov/pubmed/35740639
http://dx.doi.org/10.3390/cancers14122976

Ejemplares similares